These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 12901963)
1. The systemic treatment of advanced and metastatic bladder cancer. Hussain SA; James ND Lancet Oncol; 2003 Aug; 4(8):489-97. PubMed ID: 12901963 [TBL] [Abstract][Full Text] [Related]
2. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S; Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138 [TBL] [Abstract][Full Text] [Related]
3. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Shelley M; Cleves A; Wilt TJ; Mason M Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413 [TBL] [Abstract][Full Text] [Related]
4. Current and future perspectives in advanced bladder cancer: is there a new standard? von der Maase H Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002 [TBL] [Abstract][Full Text] [Related]
9. The present and future of combination chemotherapy in bladder cancer. Culine S Semin Oncol; 2002 Jun; 29(3 Suppl 9):32-9. PubMed ID: 12094336 [TBL] [Abstract][Full Text] [Related]
10. Systemic chemotherapy of transitional cell carcinoma of the urothelium. Brinkley WM; Torti FM Semin Surg Oncol; 1997; 13(5):365-75. PubMed ID: 9259093 [TBL] [Abstract][Full Text] [Related]
11. [New developments in chemotherapy for metastasized bladder cancer]. de Wit R Ned Tijdschr Geneeskd; 2001 Dec; 145(50):2412-7. PubMed ID: 11776665 [TBL] [Abstract][Full Text] [Related]
12. [Modern chemotherapy of invasive bladder cancer]. Géczi L Magy Onkol; 2007; 51(2):133-8. PubMed ID: 17660869 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W; J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976 [TBL] [Abstract][Full Text] [Related]
17. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438 [TBL] [Abstract][Full Text] [Related]
19. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406 [TBL] [Abstract][Full Text] [Related]
20. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]